The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise

Obesity Clinical Trial

— BALO  

Official title:

The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02418728
• Other study ID #: CME2014 /450
• Status: Completed
• Phase: N/A
• First received: March 17, 2015
• Last updated: November 17, 2016
• Start date: August 2014
• Est. completion date: November 2016

Study information

• Verified date: November 2016
• Source: Hasselt University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 35 Years to 60 Years

Eligibility

Inclusion Criteria:

• Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant

• Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive

Exclusion Criteria:

• Regular glucose lowering medication or beta blockade medication

• Presence of chronical diseases

• Orthopedic or neurological problems

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Obesity

Intervention

Other:
• subcutaneous adipose tissue microdialysis under local beta/alpha blockade
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Locations

Country	Name	City	State
Belgium	Hasselt University	Diepenbeek

Sponsors (3)

Lead Sponsor	Collaborator
Hasselt University	Jessa Hospital, Maastricht University

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subcutaneous adipose tissue microdialysis	abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.	week 1	No
Primary	Atrial natriuretic peptide (ANP) Response	measurement systemic ANP response (venous blood sampling)	week 1	No
Secondary	Central insulin sensitivity	Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)	screening	No
Secondary	Echocardiography	heart function by means of standard echocardiography	Day 1	No
Secondary	Maximal oxygen uptake (ml/O2/kg/min)	measured using indirect calorimetry and an incremental bicycle protocol	Day 1	No
Secondary	Anthropometry	body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference	screening	No
Secondary	Abdominal subcutaneous adipose tissue biopsy	biochemical, proteomics and morphological analyses	week 1	No